| Identification | Back Directory | [Name]
FGI-106
(FGI106) | [CAS]
501081-38-5 | [Synonyms]
FGI-106
FGI-106
(FGI106)
Quino[8,7-h]quinoline-1,7-diamine, N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethyl- | [Molecular Formula]
C28H38N6 | [MDL Number]
MFCD34469341 | [MOL File]
501081-38-5.mol | [Molecular Weight]
458.64 |
| Hazard Information | Back Directory | [Uses]
FGI-106 is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively[1]. | [in vivo]
FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner[1]. | Animal Model: | Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus)[1] | | Dosage: | 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg | | Administration: | Intraperitoneal injection; treatments on days 2 and 5 | | Result: | Decreased mortality from Zaire EBOV in a dose-dependent manner.
|
| [IC 50]
HIV-1 | [References]
[1] Aman MJ, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 2009 Sep;83(3):245-51. DOI:10.1016/j.antiviral.2009.06.001 |
|
|